Rituximab as maintenance therapy for patients with follicular lymphoma

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2007, Pages

  Vidal, Liat ^a   Gafter Gvili, A ^b   Leibovici, L ^b   Shpilberg, O ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RITUXIMAB;

CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; FOLLICULAR LYMPHOMA; HUMAN; MONOTHERAPY; QUALITY OF LIFE; REVIEW;

EID: 44949208429     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006552     Document Type: Review

References (13)

1. Cheson 1999 Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al.Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
2. Cleary 1985 Cleary ML, Skalar J.Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985;82:7439-43.
3. Corradini 2004 Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S, et al.Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004;22:1460-8.
4. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. [MEDLINE: 9310563].
5. Ghielmini 2004 Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al.Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103:4416-23.
6. Gordan 2005 Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005;23:1096-102.
7. Hainsworth 2002 Hainsworth JD, Litchy S, Burris HA, 3rd, Scullin DC, Jr. , Corso SW, Yardley DA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002;20:4261-7.
8. Higgins 2006 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd, 2006.
9. Lopez-Guillermo 2000 Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez MA, at al. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol 2000; 11:137-40.
10. Rambaldi 2002 Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, et al.Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002;99:856-62.
11. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Jama 1995;273:408-12.
12. Schulz 2005 Schulz H, Skoetz N, Bohlius J, Trelle S, Kober T, Greb A, Engert A. Blood (ASH Annual Meeting Abstracts). 2005; Vol. 106:351.
13. Solal-Celigny 2004 Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al.Follicular lymphoma international prognostic index. Blood 2004;104(5):1258-65. [MEDLINE: 15126323].